Tuesday, January 17, 2017

Indices closed down .30% to .65%.....

Indices closed down.

S&P 500 @ 2267.89, low 2262.81, high 2272.08

RSI @ 57.36

CMF @ 0.047

Internals were :

Down volume led by 1.17 to 1 in NYSE & 2.00 to 1 in Nasdaq

Declining stocks led by 1.23 to 1 in NYSE & 2.41 to 1 in Nasdaq

Net new 52 wk highs were leading by 89 in NYSE & 59 in Nasdaq

VIX UP 5.7% @ 11.87

Oil @ $52.48

Gold @ $1212.90

AH Futures UP

AH Asian Markets Mixed

AH Oil & Gold UP

About market, Indices were under selling pressure and internals were weak. Too many cross current for this TAPE to handle on a daily basis. Many questions about trade policies impacting industries. Try to look for opportunities, to buy quality stocks on any weakness. Trading may be a good way, to take advantage, of conflicting statements around the globe.Some sectors are getting overbought, while other sectors are becoming attractive. Try to spot these on a daily basis, it is the relative bargain which matters.

BLOG does NOT give buy or sell.

Saleem

4 comments:

stocktrader_1996 said...

Hi Saleem,

Used the rest of my cash to buy a half position of GM @ 37.25

Their earnings guidance again comes in above expectations and really shows the quality of management there now. With a P/E just above 6 and a huge buyback program, I think the downside is very limited. I'm trying to find more cash to fill up this position a bit more.

Stocktrader

Stocks100 said...

Hi Stocktrader,

Good luck with GM.

Saleem

joseph said...


Hi Stocktrader,

I am just wondering why the stock ZYNE keeps on going higher and higher. Amazing run. A great stock selection. Well done and you deserve it..

Keep up the good work.

Joseph

stocktrader_1996 said...

Hi Joseph,

Honestly I'm not exactly sure, but I think people kind of see it as the safest boat in the rough seas of biotech right now.

They have multiple catalysts this half-year with positive expectations given similarities to GWPH's already approved drugs. Also, the recent conference call and CFO's insider purchases indicated strongly that a secondary wasn't necessary which is giving investors the "green light" and scaring shorts. Valuation at $225M still remains very reasonable assuming any of the drugs come through as expected.

I am tempted to sell soon and try and rebuy lower. Waiting for now as this represents a fresh breakout and I'd like to see what it can do.

Stocktrader